door Maud van Tol | jul 19, 2023 | Geen categorie
FDA approval for nirsevimab to protect infants against RSV infections The US Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s antibody nirsevimab for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants born in...
door Maud van Tol | jul 6, 2023 | Geen categorie
Het laatste nieuws! CbusineZ and Healty.Capital invest in Amsterdam UMC spin-off ikHerstel IkHerstel an app that helps patients recover after surgery, received a capital injection by CbusineZ – the investment arm of health insurer CZ – and investment company...
door Maud van Tol | jun 12, 2023 | Geen categorie
VUmc Participations and AMC Ventures Holding contribute together to growth of ForceSense BV In December 2022, ForceSense B.V. (previously MediShield) – a market leader in laparoscopic training – received an investment from AMC Ventures Holding. ForceSense develops the...
door Maud van Tol | mei 11, 2023 | Geen categorie
Share this...FacebookTwitterLinkedin11 mei 2023Anywyse secures investment from UvA Ventures to revolutionize Audio Learning Anywyse, the Amsterdam-based Edtech startup, has secured a significant investment from UvA Ventures in its latest funding...
